The Levels of Factor XIIa Generated in Human Plasma on an Electronegative Surface Are Insensitive to Wide Variation in the Concentration of FXII, Prekallikrein, High Molecular Weight Kininogen or FXI

Summary

The contribution of the various components of the contact system in the generation of factor XIIa (FXIIa) and of kallikrein (KRN) on an electronegative surface and the release of the generated enzymes to the bulk phase was examined in mixtures of normal human plasma and plasmas congenitally deficient in these components. The incubation of normal human plasma in the presence of sulphatide vesicles (40 μM) resulted in a fast generation of amidolytic activities due to FXIIa and to KRN followed by slower first-order inactivation rates of FXIIa (k’_FXIIa) and of KRN (k’_KRN) due to the presence of esterase inhibitors. Variation of the levels of factor XII (FXII), over a wide range, showed little effect on levels of FXIIa and of KRN but no activities were detected in 100% FXII-deficient plasma. The variation of prekallikrein (PKRN) concentration showed little effect on the generation of FXIIa but the generation of KRN declined linearly with the decrease in the level of PKRN. No activities were detected on treatment of PKRN-deficient plasma. The variation in the concentration of high molecular weight kininogen (HK) showed effects on FXIIa and KRN that were qualitatively similar to those seen on variation of PKRN but 100% HK-deficient plasma generated considerable activities of both FXIIa and KRN. The variation in the concentration of factor XI (FXI) showed no effect on the generation of FXIIa, whereas KRN levels increased linearly with the contribution of FXI-deficient in normal plasma. The present results suggest that the contiguous binding of FXIIa, FXII, PKRN-HK and FXI-HK onto the electronegative surface induces a rapid generation of FXIIa and KRN. The bound PKRN-HK complex prevents the release of generated FXIIa and therefore further binding and activation of FXII from the bulk phase. Consequently, the turnover of FXII is independent of its levels in the bulk phase and is rather related to the concentration of contact surface. The generated KRN is also protected by HK. However, since the enzyme responsible for the activation of PKRN-HK is FXIIa, the levels of generated KRN are positively related to the concentration of substrate.

Keywords

Contact activation - factor XII - prekallikrein - high molecular weight kininogen - regulation of activation

• References

• 1 Wachtfogel YT, DeLa Cadena RA, Colman RW. Structural biology, cellular interactions and pathophysiology of the contact system. Throm Res 1993; 72: 1-21.
• 2 Espana F, Ratnoff OD. Activation of Hageman factor (factor XII) by sulfatides and other agents in the absence of plasma proteases. J Lab Clin Med 1983; 102: 31-45.
• 3 Tans G, Rosing J, Griffin JH. Sulfatide-dependent autoactivation of human blood coagulation factor XII (Hageman factor). J Biol Chem 1983; 258: 8215-22.
• 4 Tankersley DL, Finlayson JS. Kinetics of activation and autoactivation of human factor XII. Biochemistry 1984; 23: 273-9.
• 5 Silverberg M, Dunn JT, Garen L, Kaplan AP. Autoactivation of human Hageman factor. Demonstration utilizing a synthetic substrate. J Biol Chem 1980; 255: 7281-6.
• 6 Griep MA, Fujikawa K, Nelsestuen GL. Binding and activation properties of human factor XII, prekallikrein and derived peptides with acidic lipid vesicles. Biochemistry 1985; 24: 4124-30.
• 7 Dunn JT, Silverberg M, Kaplan AP. The cleavage and formation of activated human Hageman factor by autodigestion and by kallikrein. J Biol Chem 1982; 257: 1779-84.
• 8 Mitropoulos KA, Esnouf MP. The autoactivation of factor XII in the presence of long-chain saturated fatty acids – a comparison with the potency of sulphatides and dextran sulphate. Thromb Haemost 1991; 66: 446-52.
• 9 Ratnoff OD, Davie EW, Mallett DL. Studies on the action of Hageman factor: evidence that activated Hageman factor in turn activates plasma thromboplastin antecedent. J Clin Invest 1961; 40: 803-19.
• 10 Rosenthal RL, Dreskin OH, Rosenthal N. New haemophilia-like disease caused by deficiency of a third plasma thromboplastin factor. Proc Soc Exp Biol Med 1953; 82: 171-4.
• 11 Brunée T, La Porta C, Reddigari SR, Salemo VM, Kaplan AP, Silverberg M. Activation of factor XI in plasma is dependent on factor XII. Blood 1993; 81: 580-6.
• 12 Mitropoulos KA. Lipid-thrombosis interface. Br Med Bull 1994; 50: 813-32.
• 13 Schmaier AH, Schutsky D, Farber A, Silver LD, Bradford HN, Colman RW. Determination of the bifunctional properties of high molecular weight kininogen by studies with monoclonal antibodies directed to each of its chains. J Biol Chem 1987; 262: 1405-11.
• 14 Retzios AD, Rosenfeld R, Schiffman S. Effects of chemical modifications on the surface- and protein-binding properties of the light chain of human high molecular weight kininogen. J Biol Chem 1987; 262: 3074-81.
• 15 Kunapuli SP, DeLa Cadena RA, Colman RW. Deletion mutagenesis of high molecular weight kininogen light chain. Identification of two anionic surface binding subdomains. J Biol Chem 1993; 268: 2486-92.
• 16 Bock PE, Shore JD. Protein-protein interactions in contact activation of blood coagulation. Characterization of fluorescein-labeled human high molecular weight kininogen-light chain as a probe. J Biol Chem 1983; 258: 15079-86.
• 17 Bock PE, Shore JD, Tans G, Griffin JH. Protein-protein interactions in contact activation of blood coagulation. Binding of high molecular weight kininogen and the 5-(iodoacetamido) fluorescein-labeled kininogen light chain to prekallikrein, kallikrein, and the separated kallikrein heavy and light chains. J Biol Chem 1985; 260: 12434-43.
• 18 Mandle RJ, Colman RW, Kaplan AP. Identification of prekallikrein and high-molecular-weight kininogen as a complex in human plasma. Proc Natl Acad Sci USA 1976; 73: 4179-83.
• 19 Thompson RE, Mandle Jr R, Kaplan AP. Association of factor XI and high molecular weight kininogen in human plasma. J Clin Invest 1977; 60: 1376-80.
• 20 Griffin JH, Cochrane CG. Mechanisms for the involvement of high molecular weight kininogen in surface-dependent reactions of Hageman factor. Proc Natl Acad Sci USA 1976; 73: 2554-8.
• 21 Tait JF, Fujikawa K. Primary structure requirements for the binding of human high molecular weight kininogen to plasma prekallikrein and factor XI. J Biol Chem 1987; 262: 11651-6.
• 22 Pixley RA, Stumpo LG, Birkmeyer K, Silver L, Colman RW. A monoclonal antibody recognizing an icosapeptide sequence in the heavy chain of human factor XII inhibits surface-catalyzed activation. J Biol Chem 1987; 262: 10140-5.
• 23 Clarke BJ, Cote HCF, Cool DE, Clark-Lewis I, Saito H, Pixley RA, Colman RW, MacGillivray RTA. Mapping of a putative surface-binding site of human coagulation factor XII. J Biol Chem 1989; 264: 11497-502.
• 24 Schmaier AH, Silverberg M, Kaplan AP, Colman RW. Contact activation and its abnormalities. In: Hemostasis and Thrombosis. Colman RW, Hirsh J, Marder VJ, Salzman EW. (eds) JB Lippincott Co.; Philadelphia: 1987: 18-38.
• 25 Ragni MV, Sinha D, Seaman F, Lewis JH, Spero JA, Walsh PN. Comparison of bleeding tendence, factor XI coagulant activity and factor XI antigen in twenty-five factor XI deficient kindreds. Blood 1985; 65: 719-24.
• 26 Schmaier AH. Contact activation: a revision. Thromb Haemost 1997; 78: 101-7.
• 27 Colman RW, Schmaier AH. Contact system: a vascular biology modulator with anticoagulant, profibrinolytic, antiadhesive, and proinflammatory attributes. Blood 1997; 90: 3819-43.
• 28 Mitropoulos KA. High affinity binding of factor XIIa to an electronegative surface controls the rates of factor XII and prekallikrein activation in vitro. Thromb Res 1999; 94: 117-29.
• 29 Tans G, Janssen-Claessen T, Rosing J, Griffin JH. Studies on the effect of serine protease inhibitors on activated contact factors. Applications in amidolytic assays for factor XIIa, plasma kallikrein and factor XIa. Eur J Biochem 1987; 164: 637-42.
• 30 Mitropoulos KA, Reeves BEA, O’Brien DP, Cooper JA, Martin JC. The relationship between factor VII coagulant activity and factor XII activation induced in plasma by endogenous or exogenously added contact surface. Blood Coagul Fibrinolysis 1993; 4: 223-34.
• 31 Tans G, Rosing J, Berrettini M, Lämmle B, Griffin JH. Autoactivation of human plasma prekallkrein. J Biol Chem 1987; 262: 11308-14.
• 32 Pixley RA, Schmaier A, Colman RW. Effect of negatively charged activating compounds on inactivation of factor XIIa by C1-inhibitor. Arch Biochem Biophys 1987; 256: 490-8.
• 33 Schapira M, Scott CF, James A, Silver LD, Kueppers F, James HL, Colman RW. High molecular weight kininogen or its light chain protects human plasma kallikrein from inactivation by plasma protease inhibitors. Biochemistry 1982; 21: 567-72.
• 34 Schapira M, Scott CF, Colman RW. Protection of human plasma kallikrein from inactivation by C1 inhibitor and other protease inhibitors. The role of high molecular weight kininogen. Biochemistry 1981; 20: 2738-43.
• 35 Colman RW. Significance of the regulation of plasma kallikrein by α₂M. Ann NY Acad Sci 1994; 737: 347-67.
• 36 Blezer R, Willems GM, Cahalan PT, Lindhout T. Initiation and propagation of blood coagulation at artificial surfaces studied in a capillary flow reactor. Thromb Haemost 1998; 79: 296-301.
• 37 Mitropoulos KA, Reeves BEA, Miller GJ. The activation of factor VII in citrated plasma by charged long-chain saturated fatty acids at the interface of large triglyceride-rich lipoproteins. Blood Coagul Fibrinolysis 1993; 4: 943-51.
• 38 Mitropoulos KA, Miller GJ, Watts GF, Durrington PN. Lipolysis of triglyceride-rich lipoproteins activates coagulant factor XII: a study in familial lipoprotein-lipase deficiency. Atherosclerosis 1992; 95: 119-25.
• 39 Miller GJ, Martin JC, Mitropoulos KA, Esnouf MP, Cooper JA, Morrissey JH, Howarth DJ, Tuddenham EG. Activation of factor VII during alimentary lipemia occurs in healthy adults and patients with congenital factor XII or factor XI deficiency, but not in patients with factor IX deficiency. Blood 1996; 87: 4187-96.
• 40 Silveira A, Karpe F, Johnsson H, Bauer KA, Hamsten A. In vivo demonstration in humans that large postprandial triglyceride-rich lipoproteins activate coagulation factor VII through the intrinsic coagulation pathway. Arterioscler Thromb Biol 1996; 16: 1333-9.
• 41 Wildgoose P, Nemerson Y, Hansen LL, Nielsen FE, Glazer S, Hedner U. Measurement of basal levels of factor VIIa in hemophilia A and B patients. Blood 1992; 80: 25-8.
• 42 Miller GJ, Mitropoulos KA, Nanjee MN, Howarth DJ, Martin JC, Esnouf MP, Reeves BEA, Miller NE, Cooper JA. Very low activated factor VII and reduced factor VII antigen in familial abetalipoproteinaemia. Thromb Haemost 1998; 80: 233-8.